Abstract:
An organometallic compound, represented by Formula 1: M1(L1)n1(Ln2)n2 Formula 1 wherein M1 is a transition metal, Ln1 is a ligand represented by Formula 1-1, Ln2 is a ligand represented by Formula 2-1 or Formula 2-2, n1 is 1 or 2, and n2 is 1 or 2: wherein CY11, CY12, X31, X32, R10A, R10B, R21 to R28, R31 to R37, R41 to R44, b11, and b12 are as defined herein, and * and *′ each indicate a binding site to M1.
Abstract:
An organometallic compound, represented by Formula 1: M1(Ln1)n1(Ln2)n2 Formula 1 wherein, in Formula 1, M1 is a transition metal, Ln1 is a ligand represented by Formula 1A, Ln2 is a ligand represented by Formula 1B, n1 is 1 or 2, and n2 is 1 or 2: wherein the substituents of Formulae 1A and 1B are as provided herein in the detailed description.
Abstract:
An organometallic compound, represented by Formula 1: M1(Ln1)n1(Ln2)n2 Formula 1 wherein, in Formula 1, M1 is a transition metal, Ln1 is a ligand represented by Formula 1-1, Ln2 is a ligand represented by Formula 2-1 or 2-2, n1 is 1 or 2, and n2 is 1 or 2: wherein, in Formulae 1-1, 2-1, and 2-2, CY1, X21 to X28, X31, X32, R10, R31 to R37, R41 to R44, and b10 are as defined herein, and * and *′ each indicates a binding site to M1.
Abstract:
An organometallic compound, represented by Formula 1: M1(Ln1)n1(Ln2)n2 Formula 1 wherein, Ln1 is a ligand represented by Formula 1-1, Ln2 is a ligand represented by Formula 2-1 or 2-2, n1 is 1, 2, or 3, and n2 is 0, 1, or 2, wherein CY1 is a benzoquinoline group or a benzoisoquinoline group, X31 and X32 are each independently O or S; R10, R21 to R28, R31 to R37, R41 to R44, and b10 are as defined herein; and * and *′ each indicate a binding site to M1.
Abstract:
Provided are an organometallic compound represented by Formula 1, an organic light-emitting device including the organometallic compound, and a diagnostic composition including the organometallic compound. M1(Ln1)n1(Ln2)n2 Formula 1 Ln1 is a ligand represented by Formula 1-1, Ln2 is a ligand represented by Formula 1-2, and the other substituents are as described in the detailed description.
Abstract:
An organometallic compound represented by Formula 1: M1(Ln1)n1(Ln2)3-n1 Formula 1 wherein M1 is a first-row transition metal of the Periodic Table of Elements, a second-row transition metal of the Periodic Table of Elements, or a third-row transition metal of the Periodic Table of Elements, Ln1 is a bidentate ligand, n1 is 0, 1, or 2, and Ln2 is a ligand represented by Formula 1A: wherein A1, A2, Y1, Y2, R1 to R3, R10, R20, b10, and b20 are as provided herein, and * and *′ each indicate a binding site to a neighboring atom.
Abstract:
An organometallic compound represented by Formula 1: M(L1)n1(L2)n2 Formula 1 wherein L1 is a ligand represented by Formula 2 and L2 is a ligand represented by Formula 3; wherein in Formulae 1, 2, and 3, groups and variables are defined in the specification.
Abstract:
An organometallic compound represented by Formula 1: M(L1)n1(L2)n2 Formula 1 wherein M is a transition metal, L1 is a ligand represented by Formula 2, L2 is a monodentate ligand, a bidentate ligand, a tridentate ligand, or a tetradentate ligand, n1 is 1, 2, or 3, n2 is 0, 1, 2, 3, or 4, and Formula 2 is as described herein.
Abstract:
An organometallic compound represented by Formula 1:
M1(L1)n1(L2)n2 Formula 1
wherein, M1 is a transition metal, L1 is a ligand represented by Formula 1A, L2 is a ligand represented by Formula 1B, and n1 and n2 are each independently 1 or 2,
wherein i) X45 is C(R45) and X46 is C(R46), wherein R45 and R46 are bonded together to form a group represented by Formula 2, ii) X46 is C(R46) and X47 is C(R47), wherein R46 and R47 are bonded together to form a group represented by Formula 2, or iii) X47 is C(R47) and X48 is C(R48), wherein R47 and R48 are bonded together to form a group represented by Formula 2; ring CY4 and ring CY5 are condensed with each other, and the remaining descriptions of Formulae 1A, 1B, and 2 are as provided herein.
Abstract:
An organometallic compound represented by Formula 1:
M1(L1)n1(L2)n2 Formula 1
wherein M1 is a transition metal, L1 is a ligand represented by Formula 1A, L2 is a ligand represented by Formula 1B, and n1 and n2 are each independently 1 or 2,
wherein X1 and X2 are each independently C or N, ring CY2 and ring CY4 are each independently a C5-C30 carbocyclic group or a C1-C30 heterocyclic group, ring CY3 is a 5-membered heterocyclic group; a 5-membered heterocyclic group condensed with a C5-C30 carbocyclic group; or a 5-membered heterocyclic group condensed with a C1-C30 heterocyclic group, Y1 is O, S, Se, C(R5)(R6), N(R7), Si(R8)(R9), or Ge(R8)(R9), at least one of R12 and R13 comprises deuterium, and the other substituent groups are as described herein.